Compare FJET & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FJET | NTHI |
|---|---|---|
| Founded | 2022 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.8M | 106.0M |
| IPO Year | 2026 | 2023 |
| Metric | FJET | NTHI |
|---|---|---|
| Price | $1.76 | $3.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | ★ 1.6M | 177.7K |
| Earning Date | 11-14-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,990.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.67 | $2.96 |
| 52 Week High | $28.56 | $12.99 |
| Indicator | FJET | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 26.86 | 43.54 |
| Support Level | N/A | $3.03 |
| Resistance Level | $2.10 | $3.70 |
| Average True Range (ATR) | 0.16 | 0.34 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 33.49 | 36.84 |
Starfighters Space Inc is a commercial aerospace company based at NASA's Kennedy Space Center in Florida, with an additional base of operations at Midland International Air & Space Port in Texas, and has a fleet of seven F-104 Fighter jets that are capable of flying MACH 2+. Its activities include air launch operations, pilot and space flight training, support research, hypersonic testing, and other aerospace development programs. The company has one operating segment, which is principally the operations of F-104 Fighter jets and the development of infrastructure for orbital space launch.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.